Strategies to identify individuals with monogenic diabetes: results of an economic evaluation by Peters, J. L. et al.
1Peters JL, et al. BMJ Open 2020;10:e034716. doi:10.1136/bmjopen-2019-034716
Open access 
Strategies to identify individuals with 
monogenic diabetes: results of an 
economic evaluation
Jaime L Peters   ,1,2 Rob Anderson,3 Beverley Shields,4 Sophie King,4 
Michelle Hudson   ,4 Maggie Shepherd   ,4 Timothy James McDonald,4,5 
Ewan Pearson,6 Andrew Hattersley,4 Chris Hyde1
To cite: Peters JL, Anderson R, 
Shields B, et al.  Strategies 
to identify individuals 
with monogenic diabetes: 
results of an economic 
evaluation. BMJ Open 
2020;10:e034716. doi:10.1136/
bmjopen-2019-034716
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
034716).
Received 02 October 2019
Revised 09 January 2020
Accepted 30 January 2020
1Exeter Test Group, University of 
Exeter Medical School, Exeter, 
UK
2Collaboration for Leadership 
in Applied Health Research 
and Care South West Peninsula 
(NIHR CLAHRC South West 
Peninsula), University of Exeter 
Medical School, Exeter, UK
3ESMI (Evidence Synthesis 
& Modelling for Health 
Improvement), University of 
Exeter, Exeter, UK
4NIHR Clinical Research Facility, 
University of Exeter Medical 
School, Exeter, UK
5Royal Devon and Exeter NHS 
Foundation Trust, Exeter, UK
6Division of Molecular & Clinical 
Medicine, University of Dundee, 
Dundee, UK
Correspondence to
Dr Jaime L Peters;  
 j. peters@ exeter. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
Strengths and limitations of this study
 ► The model structure was informed by expert consul-
tation and critical appraisal of existing models.
 ► Parameter values were taken from a UK- based 
clinical study conducted alongside this economic 
evaluation.
 ► Wide- ranging sensitivity analyses were conducted.
 ► Many parameters were based on low numbers of 
patients.
 ► Evidence on effectiveness was limited.
AbStrACt
Objectives To evaluate and compare the lifetime costs 
associated with strategies to identify individuals with 
monogenic diabetes and change their treatment to more 
appropriate therapy.
Design A decision analytical model from the perspective 
of the National Health Service (NHS) in England and Wales 
was developed and analysed. The model was informed by 
the literature, routinely collected data and a clinical study 
conducted in parallel with the modelling.
Setting Secondary care in the UK.
Participants Simulations based on characteristics of 
patients diagnosed with diabetes <30 years old.
Interventions Four test- treatment strategies to identify 
individuals with monogenic diabetes in a prevalent cohort 
of diabetics diagnosed under the age of 30 years were 
modelled: clinician- based genetic test referral, targeted 
genetic testing based on clinical prediction models, 
targeted genetic testing based on biomarkers, and blanket 
genetic testing. The results of the test- treatment strategies 
were compared with a strategy of no genetic testing.
Primary and secondary outcome measures Discounted 
lifetime costs, proportion of cases of monogenic diabetes 
identified.
results Based on current evidence, strategies using 
clinical characteristics or biomarkers were estimated to 
save approximately £100–£200 per person with diabetes 
over a lifetime compared with no testing. Sensitivity 
analyses indicated that the prevalence of monogenic 
diabetes, the uptake of testing, and the frequency of home 
blood glucose monitoring had the largest impact on the 
results (ranging from savings of £400–£50 per person), 
but did not change the overall findings. The model is 
limited by many model inputs being based on very few 
individuals, and some long- term data informed by clinical 
opinion.
Conclusions Costs to the NHS could be saved with 
targeted genetic testing based on clinical characteristics or 
biomarkers. More research should focus on the economic 
case for the use of such strategies closer to the time of 
diabetes diagnosis.
trial registration number NCT01238380.
bACkgrOunD
Monogenic diabetes is a form of diabetes 
caused by a mutation in a single gene, which 
is inherited in an autosomal dominant 
manner.1 Therefore a child of an individual 
with monogenic diabetes has a 50% chance of 
inheriting the mutation (assuming the child’s 
other parent does not have the mutation). 
Mutations in glucokinase (GCK), hepatocyte 
nuclear factor 1 alpha (HNF1A) and hepato-
cyte nuclear factor 4 alpha (HNF4A) genes 
are the most common forms of monogenic 
diabetes.2 Individuals with mutations in the 
GCK gene have persistently moderately raised 
blood glucose levels from birth, that is rarely 
detrimental to health3 and does not respond 
to treatment.4 Therefore individuals with 
mutations in the GCK gene can be success-
fully treated by diet.4 Individuals with HNF1A 
or HNF4A mutations have blood glucose 
levels which increase over time and can be 
successfully treated with sulphonylureas5 but 
may, eventually, require insulin treatment.6
The minimum prevalence of monogenic 
diabetes in the UK has been estimated as 
108 cases per million.7 As it usually presents 
by 25–30 years of age,1 2 8 individuals are 
often misdiagnosed with type 1 diabetes, and 
receive insulin treatment when less invasive 
and less costly treatment is more appropriate.
The National Health Service (NHS) in 
England and Wales currently has no national 
guidelines for identifying individuals with 
monogenic diabetes. Realistic strategies are 
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Figure 1 Simplified model structure for the Ad Hoc Testing, 
Clinical Prediction Model Testing and All Testing strategies. 
IMS CDM, IMS CORE Diabetes Model.
available ranging from genetic testing of all individuals 
with diabetes to targeted genetic testing based on clinical 
characteristics9 or biochemical10 and immunological11 
tests. We report a UK- based economic evaluation of these 
realistic strategies to identify individuals with monogenic 
diabetes (defined here as mutations in GCK, HNF1A or 
HNF4A genes). The development of the model- based 
economic evaluation has been published elsewhere.12 
The economic evaluation was undertaken alongside a 
clinical study whose aims included (1) Investigating the 
prevalence of monogenic diabetes within two areas of the 
UK. (2) Measuring the effects of a change of treatment 
following a positive diagnosis of monogenic diabetes. The 
clinical study recruited 1407 individuals who were diag-
nosed with diabetes <30 years old and who were <50 years 
old at recruitment.13 Prospective quality of life using the 
EuroQol (EQ- 5D) Index, a generic measure of health 
outcome14 and glycated haemoglobin (HbA1c) data 
for 45 individuals who were diagnosed with monogenic 
diabetes within the geographical areas of the clinical 
study were collected until 12 months after the genetic test 
result. Although the clinical study collected data on clin-
ical outcomes, it was not designed, nor powered, to detect 
small changes in clinical outcomes. No statistically signifi-
cant change in the EQ- 5D Index or HbA1c before and 12 
months after changing treatment was observed making it 
impossible to confirm or refute the clinically suspected 
benefit of changing treatment in persons found to have 
monogenic diabetes, but on inappropriate treatment. 
Thus, for the main analyses, only costs are considered in 
this economic evaluation, making this a conservative anal-
ysis of the testing strategies if patient benefit does occur. 
The implications of this are considered in the discussion.
The aim of this analysis is to evaluate and compare the 
lifetime costs of different realistic strategies in the NHS 
to identify individuals with monogenic diabetes and 
change their treatment to more appropriate therapy. 
This economic evaluation has been reported in line with 
the Consolidated Health Economic Evaluation Reporting 
Standards.15
MAterIAlS AnD MethODS
Model overview
A hybrid decision model was developed from the perspec-
tive of the NHS in England and Wales. A decision tree 
was developed in MicroSoft Excel to estimate the short- 
term (16 months) costs, which allowed a maximum of 4 
months from referral to testing to change of treatment 
(for those identified as having monogenic diabetes), plus 
12 months follow- up (coinciding with the accompanying 
clinical study). The IMS Centre for Outcomes Research 
(CORE) Diabetes Model (IMS CDM) V.8.516 was used 
to estimate the lifetime costs associated with the strate-
gies. Expert consultation and explicit critical appraisal 
of existing long- term diabetes models helped to inform 
the structure of the decision model and choice of the 
IMS CDM (see Peters et al12 for more detail on model 
development). Evidence to inform the model came from 
a number of sources including published and unpub-
lished data and clinical opinion. Details on the evidence 
used in the model are given below.
Strategies and comparator
Five strategies for identifying monogenic diabetes in 
individuals who were diagnosed with diabetes under 
the age of 30 years were defined: no genetic testing 
(‘No Testing’), clinician- based genetic test referral (‘Ad 
Hoc Testing’), targeted genetic testing based on clinical 
prediction models9 (‘Clinical Prediction Model Testing’) 
or biochemical (urinary C peptide to creatinine ratio, 
UCPCR)10 and immunological (islet autoantibodies)11 
test results (‘Biomarker Testing’), blanket genetic testing 
(‘All Testing’).
The No Testing strategy is the comparator for all other 
strategies, as it represents the current policy within 
England and Wales where there is no guidance on the 
identification of individuals with monogenic diabetes. 
Thus, in this strategy all individuals remain on the 
diabetes treatment they were receiving at the start of the 
model, regardless of whether they truly have monogenic 
diabetes or not.
The Ad Hoc Testing strategy assumes no systematic 
referral of individuals for monogenic diabetes genetic 
testing. Instead, individuals are referred on an ad hoc 
basis depending on the awareness of local clinicians of 
monogenic diabetes (see figure 1). Data on referral rates 
for monogenic diabetes genetic testing in the UK7 were 
used to calculate estimates of sensitivity and specificity of 
ad hoc referral.
In the Clinical Prediction Model Testing strategy, it is 
assumed that an individual general practitioner (GP) 
would complete the online monogenic diabetes predic-
tion model (http://www. diabetesgenes. org/ content/ 
mody- probability- calculator)9 to calculate a probability of 
the individual having monogenic diabetes (see figure 1). 
Depending on the probability of the individual having 
monogenic diabetes as calculated from the prediction 
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Figure 2 Simplified model structure for the Biomarker 
Testing strategy. IMS CDM, IMS CORE Diabetes Model; 
UCPCR, urinary C peptide to creatinine ratio.
model, the GP would then refer them for monogenic 
diabetes genetic testing or not. Two versions of the predic-
tion model exist, one to distinguish type 1 diabetes from 
monogenic diabetes (version 1) and the other to distin-
guish type 2 diabetes from monogenic diabetes (version 
2). If the individual is currently receiving insulin, then 
version 1 of the prediction model is used, otherwise version 
2 is used. For each version of the prediction model, nine 
thresholds are simulated in the decision model. Thus, the 
Clinical Prediction Model Testing strategy can be evalu-
ated at 81 thresholds (9 from version 1 × 9 from version 
2) for the simulated population. The decision model can 
then be used to identify the probability threshold for the 
prediction model that maximises the costs saved using 
the Clinical Prediction Model Testing strategy compared 
with the No Testing strategy.
In the Biomarker Testing strategy individuals receive 
biochemical and/or immunological tests depending 
on their demonstrated ability to produce insulin (see 
figure 2). If individuals are currently receiving insulin 
treatment, they are offered a UCPCR test to determine 
whether they are producing insulin or not.10 Those with 
a positive UCPCR test are then offered a test for glutamic 
acid decarboxylase (GAD) and islet antigen 2 (IA2) auto-
antibodies.11 If individuals are not currently receiving 
insulin treatment it is assumed they can produce their 
own insulin and so do not require a UCPCR test. Instead, 
those individuals not on insulin treatment are offered 
a test for GAD and IA2 autoantibodies. The aim of the 
GAD and IA2 autoantibodies test is to rule out those 
individuals with type 1 diabetes who are still producing 
insulin (ie, in the ‘honeymoon’ period). Individuals not 
showing the presence of autoantibodies are then offered 
the monogenic diabetes genetic test. In the All Testing 
strategy, all individuals are offered monogenic diabetes 
genetic testing (see figure 1).
Model input parameters
Population characteristics
The main analysis (modelled Cohort 1) simulated a preva-
lent cohort of individuals in England and Wales who were 
diagnosed with diabetes when <30 years old and were 
<50 years old at the start of the model. The prevalence of 
monogenic diabetes assumed in this cohort is 2.4% (GCK 
mutation 0.7%, HNF1A mutation 1.5%, HNF4A mutation 
0.2%). A subgroup analysis (modelled Cohort 2) was 
undertaken to represent a future incident cohort who 
would have had a diagnosis of diabetes for a shorter dura-
tion than those in Cohort 1. Cohort 2 is defined as indi-
viduals diagnosed with diabetes when <30 years old and 
who were <30 years old at the start of the model, leading 
to a prevalence of 2.2% having monogenic diabetes. All 
information relevant to Cohort 2, including parameter 
values and results, are in online supplementary data 1. 
Further data on the prevalence and characteristics of 
Cohort 1 are given in online supplementary data 2.
Test characteristics
Details of the test sensitivity and specificity used in the 
model are shown in online supplementary data 3. To 
calculate the sensitivity and specificity of referral for 
monogenic diabetes genetic testing in the Ad Hoc Testing 
strategy, four data sets were used:
 ► Diabetes prevalence from unpublished data for 
Tayside, Scotland.
 ► Estimates of total population by age and area from 
national census.17
 ► Monogenic diabetes prevalence from the accompa-
nying clinical study.13
 ► Monogenic diabetes genetic test referral rates.7
The referral rates for monogenic diabetes genetic 
testing varied across the UK, with higher referral rates in 
areas where there is a strong research interest in mono-
genic diabetes, for example, the south- west of England, 
and Scotland. Estimates of sensitivity and specificity 
varied from sensitivity of 0.038 and specificity of 0.996 
(Northern Ireland) to sensitivity 0.196 and specificity 
0.977 (south- west of England) (see online supplementary 
data 3). To account for the general low rates of referral in 
the UK, we assumed the referral rates for one of the lowest 
areas, northern Ireland. In sensitivity analyses, data from 
all individual regions were used to estimate sensitivity and 
specificity for the Ad Hoc Testing strategy. However, the 
cost of increased awareness in one area compared with 
other areas is not known, and so it is not possible to esti-
mate the additional cost of increased awareness of mono-
genic diabetes in the Ad Hoc Testing strategy, such as the 
south- west of England and Scotland.
For the Clinical Prediction Model Testing strategy the 
probability thresholds of 10%–90% for the two versions 
of the test were taken from Shields et al,9 with sensitivity 
ranging from 0.5 to 0.99 and specificity ranging from 
0.65 to 0.996. All 81 combinations of probability thresh-
olds were evaluated in the decision model. No adjust-
ments were made to the clinical prediction model as the 
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population on which it would be applied (individuals 
with diabetes in England and Wales) is very similar to that 
on which it is based. In the Biomarker Testing strategy, 
sensitivity of 0.94 and specificity of 0.96 for the UCPCR 
test was used based on a UCPCR cut- off of ≥0.2 nmol/
mmol to discriminate individuals with HNF1A and HNF4A 
mutations who were insulin- treated from individuals with 
type 1 diabetes.10 Besser et al did not report on the sensi-
tivity and specificity of this cut- off to discriminate insulin- 
treated type 2 from GCK, HNF1A and HNF4A mutations, 
or to discriminate type 1 from GCK mutations. Since use 
of a different UCPCR cut- off for type 1 or insulin- treated 
type 2 would be difficult in practice (Besser et al10), we 
assumed that the UCPCR cut- off of ≥0·2 nmol/mmol 
could be used to discriminate type 1 from insulin- treated 
type 2, HNF1A and HNF4A mutations. Furthermore, 
Besser et al report that UCPCR cannot be used to discrim-
inate GCK from HNF1A and HNF4A mutations. Thus, 
we assume that the UCPCR cut- off of ≥0.2 nmol/mmol 
can be used to discriminate type 1 diabetes from insulin- 
treated type 2, GCK, HNF1A and mutations. The impact 
on the model results of using different estimates of sensi-
tivity and specificity is assessed in sensitivity analyses. Data 
from McDonald et al11 were used to inform the sensitivity 
and specificity for the GAD and IA2 autoantibody tests 
(see online supplementary data 3). For all testing strat-
egies, individuals referred for the monogenic diabetes 
genetic test were either tested for mutations in the GCK 
gene only, the HNF1A and HNF4A genes together, or all 
three genes (see online supplementary data 2).
Uptake and repeat tests
Using data from the accompanying clinical study, for 
Cohort 1, it was assumed that 8·2% of individuals would 
decline the offer of genetic testing (6.9% for Cohort 2). 
This percentage was applied to all of the strategies where 
genetic testing was an option. For the Biomarker Testing 
strategy it was assumed that 11·9% of Cohort 1 (12.8% 
of Cohort 2) individuals offered the UCPCR test and 
8·2% of Cohort 1 (6.9% of Cohort 2) individuals offered 
the autoantibody test would not accept. Estimates of the 
number of repeat tests required for both cohorts in the 
Biomarker Testing strategy are reported in online supple-
mentary data 2.
Family genetic testing
It was assumed in the model that identification of an indi-
vidual with monogenic diabetes from any of the defined 
strategies would lead to first degree family members (who 
fit the defined cohort) also being genetically tested. Once 
individuals identified from the testing strategies have 
had the genetic test and are found to have monogenic 
diabetes, their family members receive the monogenic 
diabetes genetic tests. In Cohort 1, it was assumed that for 
every 10 individuals identified by the testing strategies as 
having monogenic diabetes, a further 6·3 family members 
are genetically tested, with 5.9 of these assumed to have 
the mutation (based on UK referral rate data).7 These 
ratios were applied to the Ad Hoc Testing, Clinical Predic-
tion Model Testing and Biomarker Testing strategies.
Treatment for diabetes
The treatment pattern assumed at the model start is given 
in online supplementary data 2. These data are from the 
accompanying clinical study where the treatment pattern 
for those truly having monogenic diabetes is based on just 
45 individuals. The impact on the model results of the type 
of treatment at the start of the model is assessed in sensi-
tivity analyses. Only individuals with a positive genetic test 
were offered a treatment change, which was cessation of 
diabetes treatment for those with the GCK mutation or to 
sulphonylureas for individuals with the HNF1A or HNF4A 
mutations. Data from the clinical study informed the 
likely treatment pattern once individuals are diagnosed 
with monogenic diabetes. For Cohort 1, at 1 month after 
treatment change it was assumed that 86% of individuals 
with HNF1A or HNF4A mutations were receiving a more 
appropriate treatment, at 3 months this was 86%, at 6 
months this was 89% and at 12 months this was 77% (see 
online supplementary data 2). Some individuals having 
a positive genetic test result may not successfully change 
to sulphonylurea treatment alone and may continue to 
receive insulin.18 For individuals with HNF1A or HNF4A 
mutations it was assumed that they would require insulin 
treatment eventually, and how much insulin and when 
they would start taking it would depend on whether they 
had previously received sulphonylureas and progressed 
to insulin or had started on insulin initially. As no data 
are available, two experts in monogenic diabetes (AH and 
EP) were consulted for their opinion (see online supple-
mentary data 2). Based on data from the accompanying 
clinical study it was assumed that 93% of individuals iden-
tified to have the GCK mutation, would successfully stop 
all diabetes treatment.
Resource use
The type of NHS costs (£), inflated to 2018 prices using the 
Hospital and Community Health Services pay and prices 
index19 considered within each strategy are summarised 
in (online supplementary data 4).
All treatment costs were estimated using the reported 
doses from the clinical study and the British National 
Formulary.20 The costs associated with the tests include 
costs for the collection of blood and urine samples, costs 
of the UCPCR and autoantibody tests, and genetic test 
costs. The costs of nurse time spent providing assistance 
to those individuals with monogenic diabetes who are 
changing to a more appropriate treatment were also 
included (see online supplementary data 4) .
The costs associated with home blood glucose moni-
toring (HBGM) were also included in the model. The 
frequency of HBGM before and after diagnosis of mono-
genic diabetes, and any subsequent change in treatment, 
were estimated from the clinical study for individuals 
truly having monogenic diabetes (see online supplemen-
tary data 2). Data from the literature were used to inform 
 o
n
 August 25, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034716 on 18 March 2020. Downloaded from 
5Peters JL, et al. BMJ Open 2020;10:e034716. doi:10.1136/bmjopen-2019-034716
Open access
Table 1 Summary of the per person lifetime costs* and percentage of cases and non- cases genetically tested for each 
strategy (ordered by increasing cost of strategy)
Strategy
Total undiscounted 
costs*
Total discounted 
costs*
Incremental costs 
versus no testing 
strategy*
% who are genetically tested
With monogenic 
diabetes
Without monogenic 
diabetes
Clinical Prediction 
Model Testing†
£133 200 £53 600 −£100 92 3
Biomarker Testing £133 300 £53 600 −£100 92 8
Ad Hoc Testing £133 500 £53 700 0 6 <1
No Testing £133 600 £53 700 NA 0 0
All Testing £133 700 £54 000 £300 92 92
*Rounded to nearest £100.
†Probability thresholds chosen to maximise costs saved versus No Testing are 12.6% for type 1 versus monogenic diabetes and 75.5% for 
type 2 versus monogenic diabetes.
HBGM frequency in individuals with type 1 and type 2 
diabetes.21 22 It was assumed that individuals who have 
a GCK, HNF1A or HNF4A mutation, but did not have a 
genetic test or change treatment would have the same 
HBGM frequency as at the start of the model. Costs of 
HBGM were based on use of the Accu- Check Aviva metre 
(£16.09 for 50 strips).20
The costs of diabetes- related complications for indi-
viduals with type 1 diabetes, type 2 diabetes, and HNF1A 
or HNF4A mutations were identified from reviewing the 
published literature and using data from the National 
Schedule of Reference Costs 2016/2017. Only cost data 
from the UK were modelled in the IMS CDM (see online 
supplementary data 4). The majority of cost estimates 
from the literature were associated with uncertainty, 
mainly in inflating the costs to 2018 due to the age of 
the evidence available, therefore all of the long- term costs 
inputted into the model were rounded to the nearest £50 
to avoid spurious precision. It is assumed that individ-
uals with GCK mutations do not experience long- term 
diabetes- related complications3 and once identified as 
having a mutation in the GCK gene, they no longer incur 
the costs of diabetes- specific consultations. Data from 
Curtis 201719 and Currie et al 201023 were used to inform 
the costs of diabetes- specific consultations (see online 
supplementary data 4).
long-term events and survival
It was assumed that individuals with GCK mutations do 
not experience diabetes- related events and have the same 
mortality rate as the general population.17 Therefore inid-
viduals with GCK mutations do not enter the IMS CDM. 
For individuals with HNF1A and HNF4A mutations, due to 
limited data on long- term complications and mortality, it 
was assumed that these individuals have the same pattern 
of long- term complications and mortality as individuals 
with type 1 diabetes. Therefore individuals with HNF1A 
and HNF4A mutations were modelled using the type 1 
diabetes model in the IMS CDM.
Model outcomes
All costs (£, 2018) beyond the first year are discounted 
at a rate of 3·5% per annum to account for the prefer-
ence for deferring future costs in economic evaluations.24 
Discounted and undiscounted total costs are reported in 
the results section alongside the estimated discounted 
incremental costs per person with diabetes over a lifetime 
for each strategy compared with the No Testing strategy 
and the proportion of monogenic diabetes cases identi-
fied by each strategy.
Analysis
The results of a ‘base case’ analysis are presented, but due 
to the uncertainty surrounding many of the parameter 
estimates, alternative combinations of assumptions may 
be equally plausible. Therefore, wide- ranging one- way 
sensitivity and threshold analyses have been conducted to 
explore the different sources of uncertainty; this includes 
an analysis where an improvement in utility for those who 
successfully change treatment is assumed. Details of the 
sensitivity and threshold analyses undertaken for Cohort 
1 can be found in online supplementary data 2 (see online 
supplementary data 1 for details on Cohort 2 analyses). In 
contrast to our planned analysis,12 we decided not to do a 
probabilistic analysis because important structural uncer-
tainties in this model could not be fully captured by a 
probabilistic analysis (it would therefore be misleading).
Patient and public involvement
There was no patient and public involvement in the devel-
opment or analysis of the model.
reSultS
Cohort 1: diagnosed <30 years old, <50 years old at start of 
model
For the ‘base case’ analysis, the total discounted costs 
per person with diabetes over a lifetime were estimated 
to be £53 600–£54 000 depending on the strategy used 
(see table 1). The All Testing strategy was estimated as 
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Figure 4 Sensitivity analyses: incremental costs per person 
over a lifetime for the Ad Hoc Testing strategy versus the No 
Testing strategy. GCK, glucokinase.
Figure 5 Sensitivity analyses: incremental costs per person 
over a lifetime for the Clinical Prediction Model Testing 
strategy versus the No Testing strategy. GCK, glucokinase; 
HBGM, home blood glucose monitoring; HNF1/4A, 
hepatocyte nuclear factor 1/4 alpha.
Figure 3 Base case incremental costs (vs No Testing) and 
the proportion of monogenic diabetes cases identified for 
each strategy.
the most costly (£54,000), the cheapest options were 
the Clinical Prediction Model Testing (where the prob-
ability thresholds were chosen to maximise costs saved 
compared with No Testing) and Biomarker Testing strat-
egies (£53,600). The No Testing and Ad Hoc Testing 
strategies were both estimated as £53 700 per person with 
diabetes over a lifetime. The Ad Hoc Testing strategy was 
estimated to identify very few cases of monogenic diabetes 
(6%) compared with the All Testing strategy which was 
estimated to identify 92% of monogenic diabetes cases. 
No more than 92% of monogenic diabetes cases can be 
identified by any strategy due to the assumption that 8% 
of individuals will not accept an offer of genetic testing 
for monogenic diabetes. Family testing boosts the detec-
tion of monogenic diabetes cases to 92% in the Clinical 
Prediction Model Testing and Biomarker Testing strat-
egies. The costs saved for these two strategies over the 
No Testing strategy relate to more individuals getting a 
monogenic diabetes diagnosis and changing to receive 
more appropriate treatment which is cheaper and also 
leads to a reduction in the frequency of HBGM. The 
All Testing strategy is the most expensive since although 
more monogenic diabetes diagnoses are made, resulting 
in fewer treatment and HBGM costs, the costs of genet-
ically testing all individuals diagnosed with diabetes are 
very high.
As there are 81 different combinations of probability 
thresholds for the clinical prediction model, the combi-
nation of thresholds which maximises the costs saved for 
the Clinical Prediction Model Testing strategy have been 
reported above. In figure 3, all 81 threshold combinations 
for the clinical prediction model are shown. The Clinical 
Prediction Model Testing strategy is estimated to identify 
74%–92% of monogenic diabetes cases depending on the 
probability threshold combinations used to refer indi-
viduals for genetic testing. The lifetime costs saved per 
person with these threshold combinations compared with 
No Testing vary from £0 to £150.
Sensitivity analysis results suggest that the impacts on 
costs in the different scenarios are insensitive to wide- 
ranging, plausible changes to key model parameters, (see 
figures 4–7). No plausible parameter value changes the 
finding that the Ad Hoc Testing and Clinical Prediction 
Model Testing strategies are always estimated to save costs 
compared with the No Testing strategy. Only extreme 
assumptions on the uptake of genetic and UCPCR testing 
(just 10% uptake) suggest fewer costs are saved from 
the Biomarker Testing strategy when compared with 
the No Testing strategy. Except for assumptions on test 
uptake, the estimated cost savings are in the region of 
£0–£50 per person over a lifetime for the Ad Hoc Testing 
strategy (see figure 4), £50–£300 for the Clinical Predic-
tion Model Testing strategy (see figure 5) and £50–£250 
for the Biomarker Testing strategy (see figure 6). The All 
Testing strategy is estimated to cost an additional £150–
£350 per person over a lifetime compared with the No 
Testing strategy except when the cost of the genetic test 
is assumed to be <60% of its current cost (see figure 7).
As figures 4–7 show, the findings are most sensitive to:
 ► The estimated prevalence of monogenic diabetes 
within the cohort—increasing prevalence (from 
2.4% to 4.8%) leads to greater costs saved for the Ad 
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Figure 6 Sensitivity analyses: incremental costs per person 
over a lifetime for the Biomarker Testing strategy vs the No 
Testing strategy. GCK, glucokinase; HBGM, home blood 
glucose monitoring; HNF1/4A, hepatocyte nuclear factor 1/4 
alpha; UCPCR, urinary C peptide to creatinine ratio.
Figure 7 Sensitivity analyses: incremental costs per person 
over a lifetime for the All Testing strategy versus the No 
Testing strategy. GCK, glucokinase; HBGM, home blood 
glucose monitoring; HNF1/4A, hepatocyte nuclear factor 1/4 
alpha.
Hoc Testing, Clinical Prediction Model Testing and 
Biomarker Testing strategies compared with the No 
Testing strategy.
 ► The uptake of testing—reduced uptake leads to fewer 
costs saved for all strategies compared with the No 
Testing strategy,
 ► The frequency of HBGM pretreatment and post- 
treatment change—assuming that individuals change 
their frequency of HBGM by only a small amount after 
a diagnosis of monogenic diabetes, leads to fewer costs 
saved compared with the No Testing strategy,
 ► The proportion of individuals with monogenic 
diabetes who receive insulin before their mono-
genic diabetes diagnosis—the larger the proportion 
receiving insulin before being diagnosed as having 
monogenic diabetes, the greater the costs saved for all 
strategies compared with No Testing.
Threshold analysis results (see online supplementary 
data 2) suggest that when the genetic tests are reduced to 
approximately 35% of their current costs, the All Testing 
strategy incurs no additional costs compared with the No 
Testing strategy. However, in this situation, the Biomarker 
Testing and Clinical Prediction Model Testing strategies 
are estimated to save, approximately £150 per person 
over a lifetime, compared with the No Testing strategy. 
Reducing the percentage of individuals with monogenic 
diabetes who are receiving only insulin at the start of the 
model has little impact on the incremental costs esti-
mated: even if 10% of individuals with GCK mutations or 
10% of individuals with HNF1A or HNF4A mutations are 
on tablets at the start of the model, slight cost savings are 
still estimated with the Clinical Prediction Model Testing 
and Biomarker Testing strategies compared with the No 
Testing strategy (see figures 5 and 6).
Threshold analyses specific to the Biomarker Testing 
strategy demonstrate that once uptake of the UCPCR 
and autoantibody tests is reduced to less than 70%, the 
costs saved with the Biomarker Testing strategy compared 
with the No Testing strategy reduce. Costs saved with the 
Biomarker Testing strategy are most sensitive to reduc-
tions in the sensitivity of the UCPCR and autoantibody 
tests. Increases in the number of repeat urine or blood 
samples and tests required within the Biomarker Testing 
strategy have little impact on the estimate of costs saved 
compared with the No Testing strategy.
Cohort 2: diagnosed <30 years, <30 years at start of model
As in Cohort 1, the Clinical Prediction Model Testing and 
Biomarker Testing strategies are estimated to save £100 
per person with diabetes over a lifetime compared with 
the No Testing strategy, while the All Testing strategy is 
assumed to cost an additional £300 compared with the 
No Testing strategy. When compared with Cohort 1, 
the Clinical Prediction Model Testing and Biomarker 
Testing strategies are not estimated to save any more 
costs because of the trade- off between individuals being 
less likely to be on insulin prior to genetic testing in 
Cohort 2 (67% vs 83% in Cohort 1) even though they 
are more likely to successfully change to sulphonylureas 
than Cohort 1 (100% vs 79% in Cohort 1). Individuals in 
Cohort 2 were estimated to monitor their blood glucose 
less frequently before receiving a diagnosis of monogenic 
diabetes compared with Cohort 1, and so fewer costs are 
saved from reducing further the HBGM frequency than 
is the case for Cohort 1. See online supplementary data 
1 for further results, including sensitivity analyses which 
suggest that estimates of prevalence and testing uptake 
have the largest impact on the findings (as for Cohort 1).
DISCuSSIOn
The Clinical Prediction Model Testing and Biomarker 
Testing strategies modelled here have been estimated to 
be cost saving for identifying individuals with monogenic 
diabetes and changing their treatment compared with 
the current practice of no genetic testing. Assumptions 
about the prevalence of monogenic diabetes within the 
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simulated cohort, the uptake of testing and the frequency 
of HBGM before and after receiving a diagnosis of mono-
genic diabetes had the largest impact on the findings, 
but did not change the overall conclusions that targeted 
strategies are estimated to save costs compared with the 
No Testing or All Testing strategies. Data on prevalence 
and test uptake were taken directly from the accompa-
nying clinical study, which is the first to systematically 
estimate prevalence of monogenic diabetes in the UK.13 
Information on the frequency of HBGM before and after 
a diagnosis of monogenic diabetes is based on just a small 
number of individuals, but is currently the best evidence 
available.
This is the first UK- based economic evaluation of strat-
egies to identify individuals with monogenic diabetes. A 
published paper documented the development of the 
model and the intended analysis,12 and the minor depar-
tures from the protocol have been declared and justified. 
UK data have been used to inform many of the model 
inputs for which there was previously no credible evidence. 
However, due to the rarity of monogenic diabetes, many 
inputs specific to individuals with monogenic diabetes 
are based on very few individuals, especially for Cohort 
2, or assumptions. For instance, it was assumed that treat-
ment and HBGM frequency data taken from the clinical 
study at 12 months follow- up remained constant over time 
in the model, with additional long- term treatment data 
informed by clinical opinion. Until longer follow- up data 
are available, it is unclear what impact these assumptions 
may have on the model results.
We simulated two cohorts, both based on data from 
the clinical study. The aim of Cohort 2 was to assess the 
impact of strategies for identifying monogenic diabetes 
in individuals more recently diagnosed with diabetes 
than those in Cohort 1. Although it was anticipated that 
individuals in Cohort 2 would find it easier to change to 
more appropriate treatment (because they had not been 
on their existing treatment for a long time), we actually 
found that individuals in Cohort 2 were less likely to be 
on insulin at that point, so costs saved from changing 
treatment were smaller than for Cohort 1, even though 
more individuals changed treatment. However this anal-
ysis was limited by the low number of participants close 
to diagnosis for which data were available. Furthermore, 
the performance of the Clinical Prediction Model Testing 
and Biomarker Testing strategies are based on prevalent 
cohorts9–11 which will impact on their generalisability to 
an incident cohort (Cohort 2). Thus, there are still many 
uncertainties associated with the results, including that 
the IMS CDM has not been validated for monogenic 
diabetes, so these results should be interpreted with 
this in mind. Nevertheless, the numerous sensitivity and 
threshold analyses estimated cost savings for the Clinical 
Prediction Model Testing (when choice of thresholds was 
maximised to save costs) and Biomarker Testing strate-
gies compared with No Testing.
Naylor et al25 conducted an economic evaluation 
of genetic testing (akin to our All Testing strategy) for 
monogenic diabetes in individuals aged 25–40 years who 
were newly diagnosed with type 2 diabetes compared with 
no genetic testing from a US health system perspective. 
Individuals identified as having HNF1A or HNF4A muta-
tions who successfully transferred to sulphonylureas were 
assumed a HbA1c reduction of 16.4 mmol/mol compared 
with those not changing treatment (based on six individ-
uals at 3 months follow- up after treatment change)26 and 
a utility increase of 0·13 for transferring from insulin to 
sulphonylurea treatment (based on evidence from 519 
individuals aged 65 years and older with type 2 diabetes).27 
Naylor et al reported a gain of 0·012 quality- adjusted life- 
years (QALYs) for the testing strategy at an additional 
cost of $2400 per person over a lifetime compared with 
their no testing strategy, resulting in an incremental cost- 
effectiveness ratio of $205 000 per QALY gained.25 The 
additional costs for the genetic testing strategy in Naylor 
et al25 are much greater than the All Testing strategy in 
our evaluation ($2400 vs £300) because of differences in 
the populations simulated. In our evaluation a younger 
diabetes population is assumed, with individuals who 
truly have monogenic diabetes being more likely to be 
misdiagnosed with type 1 and receive insulin. The simu-
lated population in Naylor et al is older and explicitly 
those diagnosed with type 2, therefore are less likely to 
receive insulin treatment, so have fewer cost savings from 
changing treatment.
The health impacts assumed by Naylor et al25 are also 
different from those observed in our accompanying 
clinical study. Using the EQ- 5D Index, we found little 
evidence over the 12 months treatment change period 
for an improvement in utility associated with more appro-
priate treatment, although the EQ- 5D visual analogue 
scale and the Diabetes Treatment Satisfaction Question-
naire did suggest an improvement at 12 months. Further-
more, in the sample of 28 individuals with HNF1A or 
HNF4A mutations who successfully changed to sulphony-
lureas, no statistically significant impact on HbA1c at 12 
months after treatment change was found (mean differ-
ence of 3·43 mmol/mol (95% CI −2·18 to 9·04)). Due 
to the lack of evidence suggesting an effect on quality 
of life and HbA1c we took the decision to assume there 
were no differences in quality of life and HbA1c between 
those identified as having monogenic diabetes and subse-
quently changing treatment, and those not identified. 
Our evaluation was conservative, as evidence shows that 
changing treatment can have a substantial beneficial 
impact on individuals.28 29 A sensitivity analysis assuming 
an improvement in utility for those found to have HNF1A 
or HNF4A mutations who successfully changed treatment 
indicated <5 quality- adjusted days were gained from the 
Clinical Prediction Model, Biomarker and All Testing 
strategies compared with No Testing. However, generic 
and relatively simple quality of life measures (eg, EQ- 5D) 
are likely to be insensitive to the magnitude and type of 
changes individuals with diabetes might experience when 
changing to more appropriate treatment. Measuring 
such changes to quality of life is also limited by the ceiling 
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effect, since these individuals generally constitute a well- 
controlled, young diabetes population with a good quality 
of life. Given these limitations we have not considered 
any reductions in quality of life that may occur during the 
testing period, especially for those tested but not found to 
have monogenic diabetes.
A further limitation is in the evidence used to inform 
the sensitivity and specificity of the testing strategies. 
For example, the accuracy of antibody testing for the 
Biomarker strategy is based on a two- gate study design 
where the test is evaluated by comparing test results in 
individuals known to have a diagnosis of monogenic 
diabetes with those newly diagnosed with type 1 diabetes. 
Such study designs have been shown to lead to overstated 
accuracy estimates.30
A limitation of the Ad Hoc Testing strategy is in choosing 
the referral rates that are representative. We used referral 
rates for the area with the lowest rate of referral. We could 
have used an average referral rate across the country, but 
would not have been able to capture the relevant costs of 
the increased awareness in some areas (such as the south-
west of the UK where the referral centre for monogenic 
diabetes is based) which is linked to increased referral.
The results suggest that within the context of the NHS, 
the additional costs of genetically testing (a relatively 
large number of) individuals are likely to be offset by the 
lifetime savings from the subsequent treatment changes 
in a very small proportion of individuals. Although the 
estimated cost savings are relatively small per person 
(approximately £100–£200 over a lifetime), assuming 
there are approximately 200 000 individuals (personal 
communication) in England and Wales who are <50 years 
old and have had a diagnosis of diabetes before the age 
of 30 years, between £20 million and £40 million could 
be saved if such strategies are used. To be able to apply 
these findings to other populations the cost of the testing 
in particular will need to be updated. If the genetic test 
costs are significantly higher, then it is unclear whether 
the Clinical Prediction Model Testing and Biomarker 
Testing strategies could be considered cost saving, or even 
cost neutral. However, further collection of treatment 
pattern, HBGM frequency, HbA1c and quality of life data 
for individuals with monogenic diabetes is required to 
better inform the decision model, especially to model an 
incident cohort. Additional strategies to better identify 
those with monogenic diabetes are feasible, and in devel-
opment, but will also require evaluation for their effec-
tiveness and cost- effectiveness.
COnCluSIOnS
Targeted strategies to identify individuals with monogenic 
diabetes and change to more appropriate treatment may 
be cost saving to the NHS. However, collection of longer- 
term treatment and frequency of HBGM data would be 
valuable to reduce the main uncertainties in the model-
ling. Future work to evaluate the use of genetic testing 
strategies soon after diagnosis of diabetes would be useful 
to policy makers.
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